XTL Biopharmaceuticals acquires Psyga Bio

XTL Biopharmaceuticals has announced an agreement to acquire Psyga Bio, marking a strategic entry into the psychedelic biotechnology market. The acquisition positions XTL at a critical juncture in the burgeoning sector of psychedelic therapeutics, amidst evolving regulatory landscapes.

Under the terms of the agreement, XTL will acquire all of Psyga Bio through a share exchange that transfers a 40% equity stake in XTL to Psyga’s shareholders. Significantly, no cash will change hands at the deal’s closing. Additional shares—up to 10%—will be issued based on certain milestones, including the inception of clinical trials and the development of Ibogaine-based products. To support immediate financial requirements stemming from the acquisition, XTL has secured a $1.5 million private placement commitment.

Psyga Bio brings a strong asset base to XTL, including a pharmaceutical manufacturing facility equipped for the production of botanical and synthetic psychedelic substances, such as psilocybin and Ibogaine. Additionally, Psyga has a substantial library of over 180 unique mushroom strains and is gearing up to start patient enrollment in seven Phase 2a human clinical trials. These trials, focusing on mental health, neurological disorders, and addiction treatments, are slated to begin shortly, with notable collaborations with Technion, Rambam Health Care Campus, and Sheba Medical Center.

The acquisition coincides with pivotal changes in U.S. regulation, notably a presidential directive from April 2026 that mandates the FDA to expedite research and approval pathways for psychedelic therapies. This regulatory shift is expected to enhance the commercial viability of Psyga’s platform. By aligning with these developments, XTL aims to transform its positioning in the market, leveraging Psyga’s clinical and manufacturing capabilities to become a leading entity in this therapeutic arena.

Looking forward, the successful integration of Psyga's operations and the timely achievement of clinical milestones will be essential for XTL. As the psychedelic biotechnology field gains traction, further regulatory clarity and clinical outcomes will play crucial roles in shaping XTL's strategic trajectory and competitive stance.